We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery.
- Authors
Ndhlovu, Lishomwa C; Sinclair, Elizabeth; Epling, Lorrie; Tan, Qi Xuan; Ho, Terence; Jha, Aashish R; Eccles-James, Ijeoma; Tincati, Camilla; Levy, Jay A; Nixon, Douglas F; Hecht, Frederick M; Barbour, Jason D
- Abstract
Little is known about the manipulation of IL-17 producing CD4+ T cells (T(H)17) on a per-cell basis in humans in vivo. Previous studies on the effects of IL-2 on IL-17 secretion in non-HIV models have shown divergent results. We hypothesized that IL-2 would mediate changes in IL-17 levels among recently HIV-1-infected adults receiving anti-retroviral therapy. We measured cytokine T cell responses to CD3/CD28, HIV-1 Gag, and CMV pp65 stimulation, and changes in multiple CD4+ T cell subsets. Those who received IL-2 showed a robust expansion of naive and total CD4+ T cell counts and T-reg counts. However, after IL-2 treatment, the frequency of T(H)17 cells declined, while counts of T(H)17 cells did not change due to an expansion of the CD4+ naïve T cell population (CD27+CD45RA+). Counts of HIV-1 Gag-specific T cells declined modestly, but CMV pp65 and CD3/CD28 stimulated populations did not change. Hence, in contrast with recent studies, our results suggest IL-2 is not a potent in vivo regulator of T(H)17 cell populations in HIV-1 disease. However, IL-2-mediated T-reg expansions may selectively reduce responses to certain antigen-specific populations, such as HIV-1 Gag.
- Publication
Journal of clinical immunology, 2010, Vol 30, Issue 5, p681
- ISSN
1573-2592
- Publication type
Journal Article
- DOI
10.1007/s10875-010-9432-3